Exact Sciences (NASDAQ:EXAS) Stock Rating Upgraded by Mizuho

Exact Sciences (NASDAQ:EXAS) was upgraded by investment analysts at Mizuho to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Bank of America cut their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Barclays reduced their target price on Exact Sciences from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday. Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Guggenheim set a $60.00 price objective on Exact Sciences and gave the company a “buy” rating in a research note on Friday, March 28th. Finally, Scotiabank raised their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $69.25.

Exact Sciences Stock Down 1.9 %

Shares of NASDAQ:EXAS traded down $0.84 on Wednesday, hitting $42.90. 302,508 shares of the company’s stock were exchanged, compared to its average volume of 2,608,335. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences has a 1-year low of $39.97 and a 1-year high of $73.10. The company has a market capitalization of $7.97 billion, a PE ratio of -7.70 and a beta of 1.14. The firm’s 50-day moving average is $47.15 and its 200 day moving average is $55.97.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Sell-side analysts predict that Exact Sciences will post -0.58 EPS for the current year.

Institutional Trading of Exact Sciences

Institutional investors have recently modified their holdings of the business. Asset Planning Inc acquired a new stake in Exact Sciences in the fourth quarter valued at $40,000. Modus Advisors LLC purchased a new position in shares of Exact Sciences in the 4th quarter valued at about $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Exact Sciences in the fourth quarter valued at about $45,000. AlphaQuest LLC boosted its holdings in Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after buying an additional 913 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in Exact Sciences during the fourth quarter worth about $66,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.